Kim L. Dueholm

Kim Dueholm is a Partner in Novo Ventures, Novo A/S.

Kim Dueholm joined Novo A/S in 2000. He is a member of the board of directors of f-star GmbH and Orphazyme ApS, and a member of the editorial board of Expert Opinion on Therapeutic Patents. He was a board member of Core A/S, Neurokey A/S, Novexel S.A., Nuevolution A/S and Symphogen A/S.

Prior to joining Novo A/S, Kim spent five years with Novo Nordisk A/S in positions ranging from Patent Portfolio Analyst to Principal Scientific Analyst. His international experience includes research and venture fund experience in San Francisco, USA, and research experience in Osaka, Japan.

Kim is an intellectual property expert and holds a PhD in organic chemistry from the University of Copenhagen and an MSc in chemistry/business administration from Odense University.